stars 1 stars 2 stars 3

Neuro-Sys is a research-intensive and innovative organisation specialising in pharmacology and in advanced in vitro and in vivo models of neurodegenerative diseases, mode of action research, and drug development in the CNS and PNS fields. We provide pharmacological profiles of lead compounds and explore their underlying mechanism of action and studies to determine the neuroprotective activity. We’re dedicated to providing high-level technical expertise in a collaborative relationship with our clients and accompany you along the drug development stages, from preclinical to clinical. Our expertise: › Alzheimer’s disease (AD) › Parkinson’s disease (PD) › Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) › Multiple Sclerosis (MS) › Peripheral Neuropathies › Blood Brain Barrier DRUG DEVELOPMENT SERVICES Our experts in drug and pharmaceutical development provide expert guidance on: •The design of your drug discovery development plan (pre-clinical testing in vitro and in vivo models) •The design of your preclinical research programs (in vitro/ in vivo, mode of action) •The preclinical (Pharmacology, PK and ADME) development and early clinical designs (PoC studies) •The writing of research projects, investigator brochures (IB), IMPD, ODD submission (FDA/EMA) in neuro indication

NEURO-SYS Questions

The NEURO-SYS annual revenue was $15.6 million in 2026.

Yann Jaudouin is the CEO and Co-founder of NEURO-SYS.

34 people are employed at NEURO-SYS.

Top NEURO-SYS Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users